Paris
,
France
11 - 15 July 2026
International Society on Thrombosis and Haemostasis - 34th Congress, 2026 (ISTH)
Presentation schedule and materials
Saturday, 11 July 2026
13:00
- 13:15
CEST
OC 02.1
ORAL PRESENTATION
Concizumab prophylaxis in paediatric participants with haemophilia A/B with inhibitors in the phase 3 explorer10 study: Efficacy, safety and PK/PD results from the 32-week cut-off
Sonata Šaulytė Trakymienė1, Rukhmi Bhat2, Anthony KC Chan3, Anastasios Giakoumis4, Victor Jiménez Yuste5, Kaan Kavakli6, Maria Knudsen4, Johnny Mahlangu7, Mary Mathias8, Chiai Nagae9, Salim Mohamed Nekkal10, Nita Radhakrishnan11, Allison P Wheeler12 and Giancarlo Castaman13
MATERIALS AVAILABLE
13:45
- 14:00
CEST
OC 02.4
ORAL PRESENTATION
Mim8 (denecimig) prophylaxis in adults and adolescents with haemophilia A with or without inhibitors: Interim results from the FRONTIER4 long-term safety and efficacy study
Jerzy Windyga1, Llenalia Fernández2, Johannes Oldenburg3, Maria Mancuso4, Davide Matino5, Ilgiz Rakhmatullin2, Tadashi Matsushita6
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB3050
POSTER
A multinational, open-label study to investigate efficacy and safety of denecimig (Mim8) in adults with acquired haemophilia A: study enrolment 2026
Andreas Tiede1, Julien Bovet2, Wan Hui Ong Clausen3, Rikke Meldgaard3, Valbona Meha4, Midori Shima5,Rebecca Kruse-Jarres6
MATERIALS AVAILABLE
Coming soon
14:00
- 14:15
CEST
OC 02.5
ORAL PRESENTATION
Mim8 (denecimig) prophylaxis in children with haemophilia A with or without inhibitors: Interim safety and efficacy results from the FRONTIER4 long-term extension study
Manuel Carcao1, Meera Chitlur2, Karin Fijnvandraat3, Ida Frandsen4, Gili Kenet5, Runhui Wu6, Jay Jay Thaung Zaw4, Carmen Escuriola Ettingshausen7
MATERIALS AVAILABLE
Sunday, 12 July 2026
11:45
- 12:00
CEST
LB 02.3
ORAL PRESENTATION
Inno8, the first orally administered factor VIII mimetic shows favorable safety, pharmacokinetic, and pharmacodynamic properties in healthy male participants
Linda Ingemann1, Andrea Navarria2, Dorthe Gybel Vej Andersen1, Henrik Mikael Schyllert1, Mads Kreilgaard1, Christian Keicher3
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB1483
POSTER
The coagulation potential in the copresence of Mim8 and warfarin
Yuto Nakajima1
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB1438
POSTER
Mechanism-based functional monitoring of concizumab focusing on coagulation initiation:from comprehensive global assays to TFPI-oriented assessment
Kenichi Ogiwara1, Kuniyoshi Mizumachi1, Kana Sasai1, Keiji Nogami1
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB1207
POSTER
The effect of anti-TFPI antibodies in a novel rapid automatable clotting assay measuring the activity of TFPI and in a thrombin generation assay
Christian Mueller1, Anne Vindum Due2, Wanja Kellenberger1, Sergej Kellenberger1, Isabel Frei, Marianne Kjalke2, Amélie Ritschl1, Hans-Jürgen Kolde3
MATERIALS AVAILABLE
Coming soon
13:45
- 14:45
CEST
PB1441
POSTER
Real-world indirect cost burden and patient-reported outcomes in adults with hemophilia A in the United States - A CHESS-US analysis
Jing Voon Chen1, Emily Waters1, Sarah Brighton2, Enrico Ferri Grazzi 2,3
MATERIALS AVAILABLE
Monday, 13 July 2026
13:45
- 14:45
CEST
PB2069
POSTER
Denecimig (Mim8) restores thrombin generation into the normal range in people with haemophilia A: Post hoc analysis of the phase 3 FRONTIER2 and FRONTIER5 studies
Guy Young,1 Flora Peyvandi,2,3 Yesim Dargaud,4,5 Davide Matino,6 Keiji Nogami,7 Wan Hui Ong Clausen,8 Mirella Ezban,9 Jacob Lund,9 Cihan Ay10
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB2107
POSTER
Mim8 (denecimig) prophylaxis in adults, adolescents and children with haemophilia A with or without inhibitors: Interim patient-reported outcomes from the long-term extension study (FRONTIER4)
Cihan Ay1, Sanjay Ahuja2, Pratima Chowdary3, Meera Chitlur4,5, Llenalia María García Fernández6, Kaan Kavakli7, Ilgiz Rakhmatullin8, Chandrakala Shanmukhaiah9, Jerzy Windyga10, Samya Obaji11
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB2072
POSTER
Denecimig (Mim8) tiered dosing achieves consistent exposure and bleed control in phase 3 FRONTIER studies
Wan Hui Ong Clausen1, Julien Bovet2, Mads Kreilgaard3
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB2093
POSTER
Effects of denecimig (Mim8) and tranexamic acid in an in vitro clot lysis assay
Marianne Kjalke1, Jacob Lund1
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB2071
POSTER
Thrombin generation of hemophilia B-causing factor IX variants with non-factor therapies
Kyumin Lee1, Sebastian Leyes Porello1, Shelley Fletcher2, 3, Amy Shapiro4, Jill Johnsen2, 3, Marianne Kjalke5, Jacob Lund5, Benjamin Samelson-Jones1,6
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB2085
POSTER
Association of concizumab with tissue factor pathway inhibitor (TFPI) within platelets and the extracellular matrix (ECM)
Alan Mast1, Susan Maroney1, Julie Peterson1, Nicholas Martinez1, Maria Askmyr2, Brian Lauritzen2, Marianne Kjalke2
MATERIALS AVAILABLE
Coming soon
13:45
- 14:45
CEST
PB2115
POSTER
Physicians preferences in the treatment of hemophilia: A discrete-choice experiment
Elnara Fazio-Eynullayeva1, Kelley Myers2, Cooper Bussberg2, Jing Voon Chen1, Emily Waters1, Sanjay Ahuja3
MATERIALS AVAILABLE
Tuesday, 14 July 2026
13:45
- 14:45
CEST
PB3413
POSTER
Denecimig (Mim8) enhances in vitro thrombin generation in von Willebrand disease type 3 plasma
Jacob Lund1, Marianne Kjalke1
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB3426
POSTER
FVIIIa-mimetic bispecific antibody (Mim8) enhances thrombus formation of von Willebrand disease (VWD) under high shear flow condition.
Hiroaki Yaoi1, Kenichi Ogiwara1, Yuto Nakajima1, Keiji Nogami1, Hiromi Okada2, Jacob Lund3
MATERIALS AVAILABLE
13:45
- 14:45
CEST
PB3295
POSTER
Evaluation of physical activity and related bleeds in patients with hemophilia in the US: A real-world microhealth app study
Sanjay Ahuja1, Brigitte Brand2, Sonia Nasr3, Marc Lara4, Maissaa Janbain5, Mark Reding6, Mindy Simpson7,Javier Gonzalo4, Carla Ten4, Cléa Percier8, Federica Belmonte9, Amy Shapiro1
MATERIALS AVAILABLE
Keywords